Phase 2 Myeloma Trial, Recruiting (NCT06503107)

Phase 2 Myeloma Trial, Recruiting NCT06503107 Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Condition: Myeloma

Printed from Voxsanity (voxsanity.com.au) — NCT06503107 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myeloma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

The patient or their legal guardian is willing to participate and sign a consent form.
Aged between 18 and 75 years old.
Has been diagnosed with Multiple Myeloma (MM) according to international diagnostic standards (IMWG 2014).
Has relapsed (disease came back within 60 days of the most recent treatment, after trying three or more different types of treatment) or has disease that has not responded to treatment.
Lab tests (flow cytometry or immunohistochemistry) show that the myeloma cells have a protein called BCMA on their surface.
Has not received any antibody-based medications in the two weeks before the cell therapy.
Has a general health performance score of 0–2 on the ECOG scale, meaning the person is able to carry out daily activities at least to some degree (confirm with trial site).
Has blood counts meeting minimum levels: haemoglobin at least 70 g/L and platelets at least 30 × 10⁹/L.
Has liver, kidney, and heart/lung function meeting all of the following: kidney function within acceptable limits; heart pumping function (LVEF) of at least 50%; resting blood oxygen level above 90%; and liver enzyme and bilirubin levels within acceptable ranges.

Who may not be able to join:

Has been diagnosed with and treated for another type of cancer within the past 3 years.
Has certain heart conditions, including: atrial fibrillation; a heart attack in the last 12 months; a condition causing an abnormally long QT interval on a heart tracing; heart pumping function below acceptable levels; a clinically significant fluid build-up around the heart; or moderate-to-severe heart failure (NYHA class III or IV).
Currently has active graft-versus-host disease (GVHD), a condition that can occur after certain transplants.
Has a history of serious lung disease.
Has another advanced-stage cancer at the same time.
Has a severe or ongoing infection that cannot be brought under control.
Has a serious autoimmune disease or an inherited immune deficiency condition.
Has active hepatitis B or hepatitis C with abnormal liver function, as determined by specific lab test results.
Has HIV or syphilis.
Has a history of serious allergic reactions to biological products, including antibiotics.
Has an uncontrolled central nervous system condition, such as epilepsy, stroke, dementia, or a cerebellar disorder.
Is pregnant or breastfeeding, or the patient or their partner plans to have a child within 12 months after receiving the CAR-T cell treatment.
Has any other condition the trial doctor considers makes participation unsuitable.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 16 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 027-8572600

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06503107

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase: Phase 2

Status: Recruiting

Condition: Myeloma

Trial contact: 027-8572600

More information: https://clinicaltrials.gov/study/NCT06503107

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

The patient or their legal guardian is willing to participate and sign a consent form.
Aged between 18 and 75 years old.
Has been diagnosed with Multiple Myeloma (MM) according to international diagnostic standards (IMWG 2014).
Has relapsed (disease came back within 60 days of the most recent treatment, after trying three or more different types of treatment) or has disease that has not responded to treatment.
Lab tests (flow cytometry or immunohistochemistry) show that the myeloma cells have a protein called BCMA on their surface.
Has not received any antibody-based medications in the two weeks before the cell therapy.
Has a general health performance score of 0–2 on the ECOG scale, meaning the person is able to carry out daily activities at least to some degree (confirm with trial site).
Has blood counts meeting minimum levels: haemoglobin at least 70 g/L and platelets at least 30 × 10⁹/L.
Has liver, kidney, and heart/lung function meeting all of the following: kidney function within acceptable limits; heart pumping function (LVEF) of at least 50%; resting blood oxygen level above 90%; and liver enzyme and bilirubin levels within acceptable ranges.

Who may not be able to join:

Has been diagnosed with and treated for another type of cancer within the past 3 years.
Has certain heart conditions, including: atrial fibrillation; a heart attack in the last 12 months; a condition causing an abnormally long QT interval on a heart tracing; heart pumping function below acceptable levels; a clinically significant fluid build-up around the heart; or moderate-to-severe heart failure (NYHA class III or IV).
Currently has active graft-versus-host disease (GVHD), a condition that can occur after certain transplants.
Has a history of serious lung disease.
Has another advanced-stage cancer at the same time.
Has a severe or ongoing infection that cannot be brought under control.
Has a serious autoimmune disease or an inherited immune deficiency condition.
Has active hepatitis B or hepatitis C with abnormal liver function, as determined by specific lab test results.
Has HIV or syphilis.
Has a history of serious allergic reactions to biological products, including antibiotics.
Has an uncontrolled central nervous system condition, such as epilepsy, stroke, dementia, or a cerebellar disorder.
Is pregnant or breastfeeding, or the patient or their partner plans to have a child within 12 months after receiving the CAR-T cell treatment.
Has any other condition the trial doctor considers makes participation unsuitable.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 16 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Registry

ClinicalTrials.gov

Start date

23 April 2024

Est. completion

18 April 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of Treatment-related Adverse Events; Overall response rate (ORR) of nanobody-based biepitope CAR-T cells targeting BCMA in R/R MM; The rates of complete response (CR) of nanobody-based biepitope CAR-T cells targeting BCMA in R/R MM; Very good partial response (VGPR) of nanobody-based biepitope CAR-T cells targeting BCMA in R/R MM; Partial response rate (PR) of nanobody-based biepitope CAR-T cells targeting BCMA in R/R MM; Stable diseases (SD) of nanobody-based biepitope CAR-T cells targeting BCMA in R/R MM

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov